ArticleFrontiers in cardiovascular medicine2026
The association between C-reactive protein-triglyceride glucose index and all-cause mortality in patients with cardiovascular-kidney-metabolic syndrome: a single-center retrospective cohort study.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with cardiovascular-kidney-metabolic (CKM) syndrome have high mortality risk. The C-reactive protein-triglyceride glucose index (CTI) integrates inflammation and insulin resistance, yet its stage-specific prognostic value is undefined. Methods and results: This retrospective cohort study included 8,632 CKM patients (2020-2025), stratified by CTI quartiles. All-cause mortality was assessed using adjusted Cox models. Among 860 deaths (10.0%), CTI was an independent mortality predictor in both stage 0-3 (HR 1.68, 95% CI 1.30-2.18) and stage 4 CKM (HR 1.54, 1.33-1.77). Compared with Q1, Q4 patients had significantly higher risk (stage 0-3: HR 4.57, 2.32-8.99; stage 4: HR 2.26, 1.64-3.13). A linear dose-response relationship was confirmed ( Conclusion: CTI is a potent, independent predictor of all-cause mortality in CKM, with a linear dose-response relationship. By integrating inflammatory and metabolic pathways, it provides superior risk stratification over TyG index, highlighting its clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.